NCT05499702Not yet recruitingPhase 2
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 10 Aug 2022
- Start date
- Dec 2027
- Primary completion date
- Jun 2029
- Lead sponsor
- Adrian Vella
- Diseases
- Type 2 diabetes
- NCT number
- NCT05499702
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From Dec 2027 to the primary completion date, Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
- Contraindications to MRI (e.g. metal implants, claustrophobia).
Other illness
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Other
- Hematocrit \< 35%
- TSH \< 0.4 or \> 5.5.
- Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
Who the study is looking for
- We will recruit up to 20 weight-stable, subjects with type 2 diabetes
- BMI ≥ 28 Kg/M2
- Diabetes is managed by diet alone or a combination of oral agents
Age in the registry: 25 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.